Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, extended a long-term collaboration with a major global biopharmaceutical partner. The extended agreement will increase the current dedicated bioconjugation capacity fourfold by adding two new bioconjugation suites for the commercial supply of ADCs at Lonza’s Ibex Dedicate Biopark in Visp (CH). The extension will occupy 1500m2 of manufacturing space and will connect to key infrastructure suppo...